44 related articles for article (PubMed ID: 35220194)
21. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
22. Cancer risks associated with the germline MITF(E318K) variant.
Guhan SM; Artomov M; McCormick S; Njauw C-; Stratigos AJ; Shannon K; Ellisen LW; Tsao H
Sci Rep; 2020 Oct; 10(1):17051. PubMed ID: 33051548
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.
Ghiorzo P; Pastorino L; Queirolo P; Bruno W; Tibiletti MG; Nasti S; Andreotti V; ; Paillerets BB; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2013 Mar; 26(2):259-62. PubMed ID: 23167872
[TBL] [Abstract][Full Text] [Related]
25. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
26. A germline oncogenic MITF mutation and tumor susceptibility.
Paillerets BB; Lesueur F; Bertolotto C
Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
[TBL] [Abstract][Full Text] [Related]
27. Pathways from senescence to melanoma: focus on MITF sumoylation.
Leclerc J; Ballotti R; Bertolotto C
Oncogene; 2017 Nov; 36(48):6659-6667. PubMed ID: 28825724
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
29. Germline mutations predisposing to melanoma.
Toussi A; Mans N; Welborn J; Kiuru M
J Cutan Pathol; 2020 Jul; 47(7):606-616. PubMed ID: 32249949
[TBL] [Abstract][Full Text] [Related]
30. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
Vachtenheim J; Ondrušová L
Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
[TBL] [Abstract][Full Text] [Related]
31. [Malignant melanoma and the role of the paradoxal protein Microphthalmia transcription factor].
Denat L; Larue L
Bull Cancer; 2007 Jan; 94(1):81-92. PubMed ID: 17237008
[TBL] [Abstract][Full Text] [Related]
32. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
[TBL] [Abstract][Full Text] [Related]
33. Melanoma susceptibility genes and risk assessment.
Marzuka-Alcalá A; Gabree MJ; Tsao H
Methods Mol Biol; 2014; 1102():381-93. PubMed ID: 24258989
[TBL] [Abstract][Full Text] [Related]
34. The three M's: melanoma, microphthalmia-associated transcription factor and microRNA.
Bell RE; Levy C
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1088-106. PubMed ID: 22004179
[TBL] [Abstract][Full Text] [Related]
35. Skin Pigmentation Genetics for the Clinic.
Ainger SA; Jagirdar K; Lee KJ; Soyer HP; Sturm RA
Dermatology; 2017; 233(1):1-15. PubMed ID: 28463841
[TBL] [Abstract][Full Text] [Related]
36. MITF, the Janus transcription factor of melanoma.
Koludrovic D; Davidson I
Future Oncol; 2013 Feb; 9(2):235-44. PubMed ID: 23414473
[TBL] [Abstract][Full Text] [Related]
37. Vulvar melanoma: a report of 20 cases and review of the literature.
Wechter ME; Gruber SB; Haefner HK; Lowe L; Schwartz JL; Reynolds KR; Johnston CM; Johnson TM
J Am Acad Dermatol; 2004 Apr; 50(4):554-62. PubMed ID: 15034504
[TBL] [Abstract][Full Text] [Related]
38. Vulvar Melanoma in association with germline MITF p.E318K variant.
Koeller DR; Schwartz A; DeSimone MS; Rana HQ; Rojas-Rudilla V; Russell-Goldman E; Laga AC; Lindeman NI; Garber JE; Ghazani AA
Cancer Genet; 2022 Apr; 262-263():102-106. PubMed ID: 35220194
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]